A Bioavailability Score

Van De Waterbeemd H., 2003, Nature Rev. Drug Discovery, 2, 204, 10.1038/nrd1032

Kansy M., 1998, J. Med. Chem., 41, 1010, 10.1021/jm970530e

Artursson P., 1991, Biochem. Biophys. Res. Commun., 175, 885, 10.1016/0006-291X(91)91647-U

Overton E, 1897, Z. Phys. Chem., 22, 209

Meyer H, 1899, Arch. Exp. Pathol. Pharmakol., 42, 118, 10.1007/BF01834479

Clark D. E, 2001, Comb. Chem. High Throughput Screening, 4, 496, 10.2174/1386207013330850

Hirono S., 1994, Biol. Pharm. Bull., 17, 309

Wessel M. D., 1998, J. Chem. Inform. Comput. Sci., 38, 735, 10.1021/ci980029a

Yoshida F., 2000, J. Med. Chem., 43, 2585

Egan W. J., 2000, J. Med. Chem., 43, 3877

Wolohan P. R. N., 2003, J. Comput.-Aided Mol. Des., 17, 76

Oprea T. I., 2002, J. Comb. Chem., 4, 266, 10.1021/cc010093w

Lipinski C. A., 1997, Adv. Drug Delivery Rev., 23, 25, 10.1016/S0169-409X(96)00423-1

Navia M. A., 1996, Drug Discovery Today, 1, 189, 10.1016/1359-6446(96)10020-9

Veber D. F., 2002, J. Med. Chem.., 45, 2623, 10.1021/jm020017n

Hill A. P., 1994, Headache, 34, 308

Rosenberg, S. H.; Spina, K. P.; Condon, S. L.; Polakowski, J.; Yao, Z. et al. Studies Directed toward the Design of Orally Active Renin Inhibitors. 2. Development of the Efficacious, Bioavailable Renin Inhibitor (2s)-2- Benzyl-3- [[(1-Methylpiperazin-4-Yl)Sulfonyl]Propionyl]-3-Thiazol-4-Yl-l-Alanine Amide of (2s,3r,4s)-2-Amino-1-Cyclohexyl-3,4-Dihydroxy-6- Methylheptane (a-72517).J. Med. Chem.1993, 36, 460−467.

Camenisch G., 1998, Eur. J. Pharm. Sci., 6, 329

Sawada G. A., 1999, J. Pharmacol. Exp. Ther., 288, 1326

Paterson D. A., 1994, Quant. Structure−Act. Relat., 13, 10

Burton P. S., 1996, J. Pharm. Sci., 85, 1340, 10.1021/js960067d

Palm K., 1997, Pharm. Res., 14, 571, 10.1023/A:1012188625088

Norinder U., 1997, Pharm. Res., 14, 1791, 10.1023/A:1012196216736

Stenberg P., 1999, Pharm. Res., 16, 212

Norinder U., 1999, Eur. J. Pharm. Sci., 8, 56, 10.1016/S0928-0987(98)00059-1

Tamai I., 1998, J. Pharm. Sci., 87, 1546, 10.1021/js980186o

Zhao Y. H., 2002, J. Pharm. Sci., 91, 605, 10.1002/jps.10118

Zhao Y. H., 2001, J. Pharm. Sci., 90, 784

QMPRPLUS; Simulations plus, inc.  Lancaster, CA 93534-2902.

Cruciani G., 2000, Eur. J. Pharm. Sci., 11, S39, 10.1016/S0928-0987(00)00162-7

Clark D. E, 1999, J. Pharm. Sci., 88, 814

Clark D. E, 1999, J. Pharm. Sci., 88, 821

Norinder U., 2002, Adv. Drug Delivery Rev., 54, 313, 10.1016/S0169-409X(02)00005-4

Feher M., 2000, Intl. J. Pharm., 201, 247, 10.1016/S0378-5173(00)00422-1

Kempf D. J., 1991, Antimicrob. Agents Chemother., 35, 2214, 10.1128/AAC.35.11.2209

Benet, L. Z. Øie, S.; Schwartz, J. B. Design and Optimization of Dosage Regimens:  Pharmacokinetic Data.Goodman & Gilman's thePharmacological Basis of Therapeutics, 9th ed.; McGraw-Hill:  New York, 1996; pp 1707−1792.

Bertz R. J., 1997, Clin. Pharmacokinet., 32, 258, 10.2165/00003088-199732030-00004

Sietsema W. K, 1989, Intl. J. Clin. Pharmacol., Ther. Toxicol., 27, 211

Pearlman R. S., The University of Texas at Austin

Daylight Chemical Information Systems, Manual to Version 4.61

Martin Y. C., 2002, J. Med. Chem., 45, 4358

Leo, A.Medchem 2002 Database; Biobyte:  Claremont, CA.

Jaffe, A. J.; Spirer, H. F. Misused Statistics:  Straight Talk for Twisted Numbers; Marcel Dekker:  New York, 1987; pp 146−149.

Palm K., 1996, J. Pharm. Sci., 85, 39, 10.1021/js950285r

Egan W. J., 2002, Adv. Drug Delivery Rev., 54, 289